Mobile

A Phase 2 trial to determine if there is a lower starting dose of lenvatinib (20mg or 14mg daily) that will cause fewer side effects and work as well as a 24mg starting dose in treating adults with t...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005199-27

A Phase 2 trial to determine if there is a lower starting dose of lenvatinib (20mg or 14mg daily) that will cause fewer side effects and work as well as a 24mg starting dose in treating adults with thyroid cancer, who are not responding to treatment, or whose cancer has reappeared following an initial recovery

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine whether a starting dose of lenvatinib 20 mg or 14 mg once daily (QD) will provide comparable efficacy (based on ORR6M) with an improved safety profile compared to 24 mg QD (based on treatment-emergent adverse events [TEAEs] of Grade 3 or higher in the first 6 months after randomization).

Critère d'inclusion

  • 131I-refractory differentiated thyroid cancer (DTC)

Liens